---
document_datetime: 2026-02-20 10:31:56
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lyvdelzi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: lyvdelzi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.0369887
conversion_datetime: 2026-02-21 12:28:28.055386
docling_version:
  docling-serve: 1.13.0
  docling-jobkit: 1.11.0
  docling: 2.74.0
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 5.3.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.3-arm64-arm-64bit-Mach-O
---
## Lyvdelzi

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Renewal - 1 year /   | - Renewal - Accepted | 16/10/2025                          | 05/12/2025                                  |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/R/0000290389                      | Renewal of marketing authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |                       |                                                                                                                                                                                                               |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000282041 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 5.2 of the SmPC in order to update pharmacokinetic information based on final results from study CB8025- 21838 listed as a category 3 study in the RMP. This is an open-label study following oral dosing of seladelpar to subjects with primary biliary cholangitis (PBC) and hepatic impairment. In addition, the MAH took the opportunity to introduce additional administrative changes and corrections to the PI and Annex II. The RMP version 1.1 has also been submitted. | 02/10/2025 | 07/12/2025 | SmPC, Annex II and PL | SmPC new text Clinical PK analysis indicated seladelpar exposures (Cmax, AUC) were 2.1 to 2.5 fold higher in PBC patients with severe hepatic impairment (CP-C) after a single oral dose of 10 mg seladelpar. |
| Variation type II / EMA/VR/0000280277 | This was an application for a group of variations. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                         | 04/09/2025 | 07/12/2025 |                       |                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.b.1 Change in the specification   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.e Deletion of a specification parameter which may have a significant effect on the overall quality of the active substance and/or the finished product - Accepted                                                                                                                  |            |                   |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------------|
| Variation type IA_IN /                | This was an application for a group of variations. B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.b Primary packaging site - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.b Primary packaging site - Accepted | 25/07/2025 | EMA/VR/0000287799 |
| Variation type IB / EMA/VR/0000265794 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted C.I.z - To submit an updated ERA Report to provide Log Dow values within the full pH- range between pH 5 to 9 using the Shake Flask method (OECD 107, OPPTS 830.7550/830.7570).                                                                                                                                               | 26/06/2025 |                   |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000265714   | B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.2 Change outside the range of the currently approved pack sizes - Accepted                                                                                                                                                                                                                                                                                                                                                                                                            | 16/05/2025   | 07/12/2025   | SmPC, Labelling and PL           |                   |
|-----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|-------------------|
| Variation type IA_IN /                  | A.2 Change in the (invented) name of the medicinal product - A.2.a) for Centrally Authorised products - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 14/04/2025   | 07/12/2025   | SmPC, Annex II, Labelling and PL | EMA/VR/0000264096 |
| Variation type IA_IN EMA/VR/0000256196  | This was an application for a group of variations. B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.1 Not including batch control/testing - Accepted | 24/03/2025   | 07/12/2025   | Annex II and PL                  | /                 |